Why is xiidra so expensive

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: Xiidra (lifitegrast ophthalmic solution) is expensive primarily due to its status as a patented prescription medication for dry eye disease, with typical costs ranging from $500 to $700 per month without insurance. As a branded drug, it faces no generic competition until its patent expires, allowing manufacturer Shire (now part of Takeda) to set higher prices. Additionally, its development involved significant research and clinical trial investments, and it's one of only two FDA-approved prescription treatments specifically targeting inflammation in dry eye disease, creating limited market competition.

Key Facts

FDA approved on July 11, 2016 for treatment of signs and symptoms of dry eye disease
Typical cost is $500-$700 per month without insurance coverage
Contains 5% lifitegrast concentration in each 0.2mL single-use container
Manufactured by Shire (acquired by Takeda Pharmaceutical Company in 2019)
One of only two FDA-approved prescription treatments specifically for dry eye disease inflammation

Overview

Xiidra (lifitegrast ophthalmic solution) is a prescription medication specifically developed for treating the signs and symptoms of dry eye disease, a chronic condition affecting approximately 16 million Americans. Developed by SARcode Bioscience and later acquired by Shire Pharmaceuticals (which was subsequently purchased by Takeda Pharmaceutical Company in a $62 billion acquisition in 2019), Xiidra represents a significant advancement in ocular therapeutics. The drug received FDA approval on July 11, 2016, following extensive clinical trials involving over 2,500 patients across multiple studies. Unlike artificial tears that provide temporary relief, Xiidra targets the underlying inflammatory processes associated with dry eye disease, addressing both symptoms and cellular-level causes. The medication comes in single-use containers, with each 0.2mL dose containing 5% lifitegrast, and patients typically administer one drop in each eye twice daily.

How It Works

Xiidra operates through a novel mechanism targeting lymphocyte function-associated antigen-1 (LFA-1), a protein found on the surface of T-cells that plays a crucial role in the inflammatory response associated with dry eye disease. The active ingredient, lifitegrast, is a small molecule integrin antagonist that binds to LFA-1, preventing its interaction with intercellular adhesion molecule-1 (ICAM-1) on the surface of inflamed ocular tissues. This inhibition disrupts the inflammatory cascade at the cellular level, reducing T-cell migration and activation in the cornea and conjunctiva. By blocking this key inflammatory pathway, Xiidra decreases the production of inflammatory cytokines and reduces the cellular damage that contributes to dry eye symptoms. The medication's targeted approach represents a significant departure from traditional lubricating eye drops, addressing the root inflammatory causes rather than merely providing symptomatic relief through lubrication.

Why It Matters

Xiidra's significance extends beyond individual patient treatment to broader healthcare implications. For the estimated 16 million Americans suffering from dry eye disease, Xiidra offers a targeted therapeutic option that addresses underlying inflammation rather than just symptoms. The medication's development represented a major pharmaceutical breakthrough as one of only two FDA-approved prescription treatments specifically targeting inflammation in dry eye disease. However, its high cost creates accessibility challenges, with many patients facing substantial out-of-pocket expenses even with insurance coverage. This pricing dynamic highlights ongoing debates about pharmaceutical pricing, patent protections, and healthcare affordability in the United States. The drug's market performance and patient access issues also influence insurance formularies and treatment guidelines, affecting how dry eye disease is managed across the healthcare system.